–
Banco Pichincha announced this Friday that it will buy the first batch of rapid molecular tests to detect cases of COVID-19, developed at the Universidad Peruana Cayetano Heredia (UPCH) by neurobiologist Edward Málaga-Trillo and his team of scientists.
The rapid molecular tests of the UPCH seek to be the first developed in Peru.
In a statement, the bank reported that in recent days the team of researchers led by Málaga-Trillo exposed the various challenges encountered on the way to validate a scientific advance in our country. Faced with this situation, Banco Pichincha said that it decided to make the first contribution from the private sector to the aforementioned research project.
“The financial institution will make an advance purchase of 500 rapid molecular tests, which will be applied among the personnel of its different offices”, he indicated.
“As a sign of its confidence in the research carried out by the Málaga-Trillo team, Banco Pichincha will also make a capital contribution to promote the validation and production process of rapid molecular tests. In total, Banco Pichincha will contribute S / 55,000 to the research project “he added.
Julio Malo, general manager of Banco Pichincha, highlighted that the financial institution maintains a permanent social commitment and a firm intention to inspire and reward trust.
“Today we have the privilege of being the first private company to support this valuable research project, but by no means do we want to be the only one. We call on all entrepreneurs to join this initiative that can immediately impact the lives of all Peruvians “the executive said in the statement.
The rapid molecular tests in which the UPCH, Málaga-Trillo and their team of scientists are working, will have a higher level of portability, a lower cost compared to the standard molecular test and will not require a swab. This will allow taking them to more Peruvians, after completing their validation path.
“We are receiving the pleasant news of this support since yesterday. We have to try to reach everyone with the same efficiency. Therefore, the goal is to produce at least one million tests, so that everyone in need can access this technology. The cost will depend on an unprecedented production process in Peru “, said the neurobiologist Málaga-Trillo.
THIS VIDEO MAY INTEREST YOU
– .
